By Puyaan Singh and Christy Santhosh Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 ...
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
UnitedHealth Group, Inc’s. UNH Optum Rx is expanding its offerings for patients with the introduction of two additional HUMIRA biosimilars. Effective Jul 1, Optum Rx will offer three biosimilar ...
By Puyaan Singh and Christy Santhosh Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday ...
CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results